Patents by Inventor Guido KOHLA

Guido KOHLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides modulating SIGLEC dependent immune responses
    Patent number: 11738069
    Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: August 29, 2023
    Assignee: OCTAPHARMA AG
    Inventors: Christoph Kannicht, Stefan Winge, Guido Kohla, Barbara Solecka-Witulska
  • POLYPEPTIDES MODULATING SIGLEC DEPENDENT IMMUNE RESPONSES
    Publication number: 20210275644
    Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Applicant: OCTAPHARMA AG
    Inventors: Christoph KANNICHT, Stefan WINGE, Guido KOHLA, Barbara SOLECKA-WITULSKA
  • Polypeptides modulating SIGLEC dependent immune responses
    Patent number: 11013789
    Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: May 25, 2021
    Assignee: OCTAPHARMA AG
    Inventors: Christoph Kannicht, Stefan Winge, Guido Kohla, Barbara Solecka-Witulska
  • POLYPEPTIDES MODULATING SIGLEC DEPENDENT IMMUNE RESPONSES
    Publication number: 20190201495
    Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
    Type: Application
    Filed: May 22, 2017
    Publication date: July 4, 2019
    Applicant: OCTAPHARMA AG
    Inventors: Christoph KANNICHT, Stefan WINGE, Guido KOHLA, Barbara SOLECKA-WITULSKA
  • Preparation comprising factor VIII and Von Willebrand factor peptides
    Patent number: 10251940
    Abstract: A composition comprising a complex of Factor VIII and one or more Von Willebrand Factor peptides, wherein the Von Willebrand Factor peptides comprise at least the amino acids 764 to 1035 and 1691 to 1905 of SEQ ID No. 1 but not amino acids 2255 to 2645 of SEQ ID No. 1.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: April 9, 2019
    Assignee: Octapharma AG
    Inventors: Christoph Kannicht, Barbara Solecka, Guido Kohla, Stefan Winge
  • PREPARATION COMPRISING FACTOR VIII AND VON WILLEBRAND FACTOR PEPTIDES
    Publication number: 20180185455
    Abstract: A composition comprising a complex of Factor VIII and one or more Von Willebrand Factor peptides, wherein the Von Willebrand Factor peptides comprise at least the amino acids 764 to 1035 and 1691 to 1905 of SEQ ID No. 1 but not amino acids 2255 to 2645 of SEQ ID No. 1.
    Type: Application
    Filed: June 8, 2015
    Publication date: July 5, 2018
    Applicant: OCTAPHARMA AG
    Inventors: Christoph KANNICHT, Barbara SOLECKA, Guido KOHLA, Stefan WINGE